DMAAU
Drugs Made In America Acquisition Corp.
Key Financials
Net Income
$5.9M
↑ 2222.8%
Operating Income
$-2816013
↓ 906.3%
Total Liabilities
$7.3M
↑ 814.5%
Cash & Equivalents
$20280.00
N/A
Total Assets
$239.9M
↑ 43456.4%
Shareholders' Equity
$-7263981.00
↓ 2866.8%
EPS (Diluted)
$-0.03
N/A
Operating Cash Flow
$-539187.00
↓ 213.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 425 | 9/14/2026 | View on SEC |
| 8-K | 9/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 425 | 7/20/2026 | View on SEC |
| 8-K | 7/20/2026 | View on SEC |
| SCHEDULE 13G | 6/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DMAAU |
| Company Name | Drugs Made In America Acquisition Corp. |
| CIK | 2028614 |
| Sector | Blank Checks |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 6770 |
| SIC Description | Blank Checks |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 646-726-7074 |